La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
IPO Year: 1994
Exchange: NASDAQ
Website: lajollapharmaceutical.com
| Date | Price Target | Rating | Analyst |
|---|
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou
Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. Corporate Progress Net Product Sales: For the three months ended March 31, 2022, La Jolla's net product sales were $10.4 million, up 21% from the same period in 2021. GIAPREZA U.S. Net Product Sales: For the three months ended March 31, 2022, GIAPREZA U.S. net product sales were $7.7 million, up 13% from the same period in 2021. XERAVA U.S. Net Product Sales: For the three months ended
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. Corporate Progress Record Fourth Quarter and Full Year Net Product Sales: La Jolla had record net product sales for the three and twelve months ended December 31, 2021. For the three and twelve months ended December 31, 2021, La Jolla's net product sales were $12.1 million and $43.5 million, respectively, compared to $11.0 million and $33.4 million, respectively, for the same
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 and highlighted corporate progress. Corporate Progress Increased Net Product Sales: For the three and nine months ended September 30, 2021, La Jolla's net product sales were $11.8 million and $31.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales for the thre
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and highlighted corporate progress. Corporate Progress Positive Net Cash Provided by Operating Activities: La Jolla's net cash provided by (used for) operating activities for the three and six months ended June 30, 2021 was $7.1 million and $24.3 million, respectively, compared to $(8.4) million and $(20.6) million, respectively, for the same periods in 2020. La Jolla's net cash provided by (used for) operating activi
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jolla's net cash provided by (used for) operating activities for the three months ended March 31, 2021 was $17.2 million, compared to $(12.2) million for the same period in 2020. La Jolla's net cash provided by (used for) operating activities excluding net receipts in connection with license agreements and payments related
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. Corporate Progress Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe: In January 2021, La Jolla Pharmaceutical Company announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) entered into an exclusive licensing agreement with PAION AG and its who
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer. "We are thrilled to have Tony join our team here at La Jolla," said Larry Edwards, President and Chief Executive Officer of La Jolla. "Tony's clinical experience, operational leadership and in-depth knowledge of critical care medicine are key to helping La Jolla grow net sales of GIAPREZA and XERAVA and become a leader in the critical care space." "I look forward to working with the La Jolla team to continue to
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13G/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13G/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
Chardan Capital resumed coverage of La Jolla Pharmaceutical with a rating of Buy and set a new price target of $15.00
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercializ
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou
Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. Corporate Progress Net Product Sales: For the three months ended March 31, 2022, La Jolla's net product sales were $10.4 million, up 21% from the same period in 2021. GIAPREZA U.S. Net Product Sales: For the three months ended March 31, 2022, GIAPREZA U.S. net product sales were $7.7 million, up 13% from the same period in 2021. XERAVA U.S. Net Product Sales: For the three months ended
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. Corporate Progress Record Fourth Quarter and Full Year Net Product Sales: La Jolla had record net product sales for the three and twelve months ended December 31, 2021. For the three and twelve months ended December 31, 2021, La Jolla's net product sales were $12.1 million and $43.5 million, respectively, compared to $11.0 million and $33.4 million, respectively, for the same
La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company's common stock. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. "The decision to repurchase shares reflects our confidence in our team and the ability to execute against our strategic initiatives for growth, which is supported by the strength of our balance sheet," said Larry Edwards, President and Chief Executive Officer of La Jolla. About La Jolla Pharmaceutical Company La Jol
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 and highlighted corporate progress. Corporate Progress Increased Net Product Sales: For the three and nine months ended September 30, 2021, La Jolla's net product sales were $11.8 million and $31.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales for the thre
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer. "We are thrilled to have Tony join our team here at La Jolla," said Larry Edwards, President and Chief Executive Officer of La Jolla. "Tony's clinical experience, operational leadership and in-depth knowledge of critical care medicine are key to helping La Jolla grow net sales of GIAPREZA and XERAVA and become a leader in the critical care space." "I look forward to working with the La Jolla team to continue to
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and highlighted corporate progress. Corporate Progress Positive Net Cash Provided by Operating Activities: La Jolla's net cash provided by (used for) operating activities for the three and six months ended June 30, 2021 was $7.1 million and $24.3 million, respectively, compared to $(8.4) million and $(20.6) million, respectively, for the same periods in 2020. La Jolla's net cash provided by (used for) operating activi
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jolla's net cash provided by (used for) operating activities for the three months ended March 31, 2021 was $17.2 million, compared to $(12.2) million for the same period in 2020. La Jolla's net cash provided by (used for) operating activities excluding net receipts in connection with license agreements and payments related
15-12G - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
8-K - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
SC 14D9/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 14D9/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
10-Q - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercializa
Gainers Kaspien Holdings Inc. (NASDAQ:KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. Pliant Therapeutics, Inc. (NASDAQ:PLRX) shares surged 159% to close at $23.00 on Monday after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ:LJPC) climbed 81% to close at $6.14 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ:ITRM) gained
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE:ENIC), up 3% and UGI Corp (NYSE:UGI) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE:AZZ) reported better-than-expected earnings for its first quarter on Monday.
Gainers Pliant Therapeutics (NASDAQ:PLRX) stock moved upwards by 104.5% to $18.16 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 59.3 million shares, making up 20293.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $656.7 million. La Jolla Pharmaceutical (NASDAQ:LJPC) stock rose 81.12% to $6.14. As of 13:30 EST, this security is trading at a volume of 4.6 million shares, making up 7878.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $156.9 million. Iterum Therapeutics (NASDAQ:ITRM) stock increased by 71.62% to $0.41. As of
U.S. stocks traded lower midway through trading following the release of jobs report on Friday. The Dow traded down 0.50% to 31,180.09 while the NASDAQ fell 2.08% to 11,392.80. The S&P also fell, dropping, 1.15% to 3,854.54. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Health care shares slipped by just 0.2% on Monday. Meanwhile, top gainers in the sector included Pliant Therapeutics, Inc. (NASDAQ:PLRX), up 113% and Nyxoah S.A. (NASDAQ:NYXH) up 11%. In trading on Friday, communication services shares dipped by 2.3%. Top Headline AZZ Inc (NYSE:AZZ) reported better-than-expected earnings for its first quarter on Mo
Gainers Pliant Therapeutics, Inc. (NASDAQ:PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ:LJPC) gained 80.9% to $6.13 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ:ITRM) surged 71.8% to $0.4124 after the company announced that it has reached an agreement with the FDA under the special protocol assessment process on the design, endpoints and statistical
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June. The Dow traded down 0.38% to 31,220.54 while the NASDAQ fell 1.67% to 11,441.36. The S&P also fell, dropping, 0.93% to 3,862.94. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Health care shares slipped by just 0.1% on Monday. Meanwhile, top gainers in the sector included Pliant Therapeutics, Inc. (NASDAQ:PLRX), up 117% and Nyxoah S.A. (NASDAQ:NYXH) up 14%. In trading on Friday, communication services shares dipped by 2%. Top Headline AZZ Inc (NYSE:AZZ) reported better-than-expected earnings for its first quart
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus European Regulator Recommend Additional Booster Doses of mRNA COVID-19 Vaccines The European Centre for Disease Prevention & Control and the European Medicines Agency have recommended second booster doses of mRNA COVID-19 vaccines for people between 60 and 79. In April 2022, the agencies recommended that people over 80 be considered for a second booster. The move comes after a new wave is underway in Europe, with increasing hospital and intensive care unit rates. Perrigo Files US Application For First OTC Birth Control Pill Perrigo Company plc's (NYSE:PRGO) HRA Pharma has submitted its ap
Today's 5 Stock Ideas: Digital World Acquisition Corp. (DWAC) - A play on competition (or a lack of competition) in the social media space. Big news in the space over the weekend was that Elon Musk terminated his deal to buy Twitter (TWTR). Shares of Digital World, the special purpose acquisition corporation (SPAC) that will merge with Trump Media and its Truth Social social media platform, were up about 15% on the report. JP Morgan (JPM) - Will kick off the big bank earnings season on Thursday of this week. Investors can expect JP Morgan's results to be out before 7 a.m. EDT on Thursday. Roblox (RBLX) - A play on some positive analyst commentary on Friday of last week.